Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | AB248 + Personalized cancer vaccine + Poly ICLC |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| AB248 | AB-248|AB 248|etakafusp alfa | AB248 is a fusion protein comprised of an anti-CD8 antibody fused to an IL-2 mutein, which preferentially targets CD8+ T-lymphocytes, potentially resulting in increased antitumor immune response (Cancer Res 2022;82(12_Suppl):Abstract nr 3518). | ||
| Personalized cancer vaccine | Personalized cancer vaccines are vaccines generated from patient-specific tumor antigens, which may enhance immune response against those tumors (PMID: 29567706, PMID: 29111369). | |||
| Poly ICLC | Hiltonol | Hiltonol (poly ICLC) is a synthetic double stranded RNA complex, which induces interferon production and stimulates anti-tumor immune response (PMID: 22126373). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07300475 | Phase I | Personalized cancer vaccine + Poly ICLC AB248 + Personalized cancer vaccine + Poly ICLC Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab Cyclophosphamide + Doxorubicin + Pembrolizumab | Personalized Cancer Vaccine (PCV) Strategy in Triple Negative Breast Cancer Patients | Not yet recruiting | USA | 0 |